Latanoprost (latanoprost)

For the treatment of open-angle glaucoma or ocular hypertension, the usual adult dosage of latanoprost is 1 drop of a 0.005% ophthalmic solution or emulsion (1.5 mcg) in the affected eye(s) once daily in the evening.

If the target intraocular pressure (IOP) is not achieved, alternative or additional ocular hypotensive agents may be required. (See Uses: Ocular Hypertension and Glaucoma.) However, concomitant use of 2 or more prostaglandin analogs is not recommended. When latanoprost is used in fixed combination with netarsudil, the usual adult dosage is 1 drop of an ophthalmic solution containing netarsudil 0.02% and latanoprost 0.005% in the affected eye(s) once daily in the evening.

Patients should be instructed that topical ophthalmic preparations containing latanoprost should be applied no more frequently than once daily since more frequent dosing may reduce the IOP-lowering effect of the drug or cause paradoxical elevation of IOP. If the patient misses a dose, the usual schedule should be continued with the next dose applied the following evening.

Latanoprost is applied topically to the eye as an ophthalmic solution or emulsion. Latanoprost also is commercially available in fixed combination with netarsudil for topical application to the eye as an ophthalmic solution. Care should be taken to avoid contamination of the dispensing container. (See Cautions: Precautions and Contraindications.)

Latanoprost ophthalmic solution and netarsudil and latanoprost fixed-combination ophthalmic solution contain benzalkonium chloride, which may be absorbed by some contact lenses. The manufacturers of latanoprost ophthalmic solution or emulsion and netarsudil and latanoprost fixed-combination ophthalmic solution state that contact lenses should be removed prior to administration of each dose of these preparations but may be reinserted 15 minutes after the dose.

If the patient is receiving more than one topical ophthalmic preparation, the preparations should be administered at least 5 minutes apart.

No dosing information is available for this tab.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

There is no enhanced messaging for this drug.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

There are no moderate contraindications for this drug.

There is no enhanced messaging for this drug.

There are no severe adverse reactions for this drug.

There are no less severe adverse reactions for this drug.

No enhanced messaging available.

No enhanced messaging available.

Latanoprost has been embryocidal in rabbits when given in dosages greater than 15 times the maximum human dose. In rabbits given latanoprost dosages 80 times the maximum human dose, approximately 25% of dams had no viable fetuses.

There are no adequate and well-controlled studies to date evaluating latanoprost in pregnant women, and the drug should be used during pregnancy only when the potential benefits justify the possible risks to the fetus.

It is not known whether latanoprost or its metabolites are distributed into milk following topical application to the eye or whether the drug has any effects on the breast-fed infant or on milk production.

Latanoprost ophthalmic solution or emulsion should be used with caution in nursing women.

The manufacturer of netarsudil and latanoprost fixed-combination ophthalmic solution states that the developmental and health benefits of breast-feeding should be considered along with the mother's clinical need for the drugs and any potential adverse effects of the drugs on the breast-fed infant.

No enhanced messaging available.